论文部分内容阅读
Ibritumomab tiuxetan (Zevalin) is currently indicated for the treatment of relapsed or refractory low grade or follicular B-cell Non-Hodgkins lymphoma (NHL), and previously untreated follicular NHL in patients who achieve partial or complete response to first-line chemotherapy.The remarkable efficacy of a single dose of Ibritumomab tiuxetan was evident from early studies.Ibritumomab tiuxetan had shown superior efficacy when compared to rituximab (85% vs.53% ORR) in a randomized clinical trial in relapsed or refractory follicular B-cell lymphoma patients.Ibritumomab tiuxetan also showed high efficacy (74% ORR) in Rituximab-refractory follicular B-cell lymphoma patients.The results of Front-line Indolent Trial (FIT) have also been impressive, the latest update, following a 75.7 month median follow up, showing flattening ofcurve indicating cure.Realizing the potential of Ibritumomab tiuxetan, the lymphoma research community has been exploring the utility of Ibritumomab tiuxetan in various clinical settings, with promising results.Among the most exciting studies are: 1) an Italian Cooperative Study where in, for the first time, in Newly diagnosed, untreated follicular NHL patients, a single dose of Ibritumomab tiuxetan alone has been shown to give an ORR of 93% (45/48) with a CR rate of 82% (41/48), 2) a Phase 2 study where in addition of Ibritumomab tiuxetan to the BEAM conditioning regimen preceding autologous stem cell transplantation has been shown to give significant improvement in OS (91% vs.62% at 2 years) in high risk DLBCL patients and 3) a phase 2 study where in consolidation therapy with Ibritumomab tiuxetan following R-CHOP has been shown to improve PFS as well as OS in elderly high risk patients with untreated DLBCL.These studies could eventually lead to a paradigm shift in lymphoma treatment.Another important recent development with regard to the use of Ibritumomab tiuxetan has been USFDA approval for the removal of the requirement for pretreatment biodistribution evaluation, more commonly referred to as the bioscan.Removal of the bioscan requirement will simplify Ibritumomab tiuxetan treatment regimen avoiding the need for sophisticated equipment and would facilitate wider use of Ibritumomab tiuxetan so that larger number of lymphoma patients are benefitted.